Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/127550
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Castellote Alonso, José | - |
dc.contributor.author | Ariza Cardenal, Javier | - |
dc.contributor.author | Rota Roca, Rosa | - |
dc.contributor.author | Girbau, Anna | - |
dc.contributor.author | Xiol Quingles, Xavier | - |
dc.date.accessioned | 2019-01-23T11:37:40Z | - |
dc.date.available | 2019-01-23T11:37:40Z | - |
dc.date.issued | 2008-08-28 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | http://hdl.handle.net/2445/127550 | - |
dc.description.abstract | Ezetimibe is the first member of a new family of lipid-lowering drugs that inhibits uptake of dietary and biliary cholesterol. It was approved by the FDA in 2002 for hypercholesterolemia alone or in combination with statins. Its use has been spreading over the last years. Ezetimibe was considered a safe drug. We report a case of a woman who developed a serious hepatocellular drug-induced liver disease after 4 mo therapy with 10 mg daily of ezetimibe. After withdrawal of the drug, the patient recovered slowly. Ezetimibe may produce serious toxic hepatitis and prompt withdrawal is mandatory in case of a significant abnormality in liver testing after beginning or during treatment with ezetimibe. | - |
dc.format.extent | 2 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Baishideng Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3748/wjg.14.5098 | - |
dc.relation.ispartof | World Journal of Gastroenterology, 2008, vol. 14, num. 32, p. 5098-5099 | - |
dc.relation.uri | https://doi.org/10.3748/wjg.14.5098 | - |
dc.rights | cc-by-nc (c) Castellote Alonso, José et al., 2008 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Hepatitis | - |
dc.subject.classification | Efectes secundaris dels medicaments | - |
dc.subject.classification | Malalties del fetge | - |
dc.subject.other | Hepatitis | - |
dc.subject.other | Drug side effects | - |
dc.subject.other | Liver diseases | - |
dc.title | Serious drug-induced liver disease secondary to ezetimibe | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 636294 | - |
dc.date.updated | 2019-01-23T11:37:40Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 18763297 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
636294.pdf | 478.79 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License